TOR THERAPEUTICS
Our Mission is Healthy Aging
OUR STORY
A Novel Approach
Welcome!
We are Drs. Jeffrey Melin and Nancy Young, a husband and wife physician team. We founded TOR Therapeutics in 2015 to treat neurodegenerative disease. Our company is developing a novel fixed dose combination of two mTORC1 inhibitors. Our lead focus is to treat patients with Alzheimer's Disease to maintain cognitive function. We are also targeting other neurodegenerative disorders driven by mTORC1 hyperactivation.
"THE OTHER PANDEMIC"
BARRON'S Cover Story, 2/8/2021
Most people don’t realize that it takes decades for Alzheimer’s disease to fully develop. It begins with the accumulation of abnormal proteins (amyloid and tau) causing brain inflammation (neuroinflammation) leading to brain destruction. Once brain destruction occurs, it is irreversible—you can’t recover lost brain tissue. There are at least 1 in 5 Americans over the age of 50 who have amyloid and tau accumulating in their brains producing neuroinflammation and they don’t even know it. Many will go on to develop cognitive impairment within the next one to two decades. As baby boomers age, we are all in a race against time to develop early screening tests and treatments for Alzheimer’s disease before it becomes one of the greatest public health pandemics of the century. Very recently, new blood tests are allowing us to easily detect who is at risk for developing dementia due to amyloid and tau accumulation, which will allow for the development of new treatments for this disease.
OUR VISION
Our experimental drug, RMF™, is intended for development as an oral, once-a-day pill for chronic use, to treat early patients with Alzheimer's disease and maintain cognitive function. The treatment concept is analogous to how statins are currently used to prevent future heart attacks, prescribed for both prevention and treatment of heart disease. We believe that success is more likely if we begin treatment as early as possible in the course of the disease (known as the AD Continuum) before brain destruction occurs. RMF™ components have anti-aging and anti-inflammatory properties, which is another way to fight brain tissue loss (neurodegeneration). Patent protection for RMF™ extends through 2036 with new patents being filed.
Our company, TOR Therapeutics, is seeking investment to continue development of RMF™.
Alzheimer’s clinical trials are expensive, but our team is experienced, and we believe our clever clinical trial designs can speed up the development program, potentially having a commercially available product within 6 years. We are looking for the right investors who can help us get there.
MEET THE FOUNDERS
JEFFREY M. MELIN MD, MPH, MBA
CEO/Chief Medical Officer and Founder
Dr. Melin has decades of experience developing numerous approved drugs and has held leadership roles at Merck, Wyeth, Pfizer, and UCB. His industry and prior experience as a practicing clinical immunologist and rheumatologist have provided him with the insight to harness late breaking science in order to tackle neuroinflammatory degenerative disease. He holds numerous patents integral to the TOR Therapeutics pipeline and is experienced in conducting efficient drug development programs. Dr. Melin's father and wife's mother died from Alzheimer's disease. He is determined to develop a treatment that will change the clinical course of this disease.
NANCY A. YOUNG, MD
Chief Operating Officer and Founder
Dr. Young is Emeritus Chair of Pathology at Einstein Healthcare Network, a 1000+ bed multi-hospital healthcare system and served as Full Professor of Pathology at Thomas Jefferson University. As a former Senior Member at Fox Chase Cancer Center, she was a member of their Institutional Review Board, for review and oversight of all clinical trials. Dr. Young is recognized for her advancements in Pathology and Laboratory Medicine, having authored numerous original publications, and for her organizational leadership, having served as president of two major medical societies (American Society of Cytopathology and PA Association of Pathologists) and as a governor of the College of American Pathologists. Dr. Young has been an invited speaker at numerous medical forums on scientific as well as regulatory and operational topics such as state and federal legislative affairs affecting medical practice and LEAN process improvement. Dr. Young cared for her mother, also a physician, who succumbed to Alzheimer's disease. She is on a quest to make screening, diagnosis, and early treatment of this disease a reality.
FOR MORE INFORMATION
Please contact us for more information about our company and investment opportunities.
TOR Therapeutics Forward Looking Statement
The information contained in the TOR Therapeutics website was obtained by or on behalf of TOR Therapeutics (“TOR Therapeutics Material”). Any estimates and projections contained herein have been prepared by TOR Therapeutics and involve significant elements of subjective judgment and analysis, which may or may not be correct. TOR Therapeutics makes no representation or warranty, expressed or implied, as to the accuracy or completeness of the information contained in the TOR Therapeutics Material, and nothing contained herein is, or shall be relied upon as, a promise or representation, whether as to the past, present, or the future. The TOR Therapeutics Material does not purport to contain all of the information that may be required to evaluate an investment transaction in TOR Therapeutics and any recipient of the TOR Therapeutics Material should conduct its own independent analysis of TOR Therapeutics products/services and the data contained or referred to in the TOR Therapeutics Material.
The fixed dose combination drug described herein is experimental. Additional studies are required to make any definitive conclusions about safety or efficacy. This drug is not approved by the FDA. All statements herein regarding this product are subject to FDA IND Review.